Inside the Current Issue

Cover Story
Managing critical care supply tensions
Self Study Series
Purchasing Connection
Resources
Show Calendar
HPN Hall of Fame
HPN ProductLink
Classifieds
Issue Archives
Advertise
About Us
Home
Subscribe

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Email Newsletter

For Email Marketing you can trust
Special Event Photos
Contact Us
KSR Publishing, Inc.
Copyright © 2012

People, Places, Processes & Products that Influence the Supply Chain

 

INSIDE THE CURRENT ISSUE

May 2010

Letters

Dear Editors,

Your recent HPN Daily Update included a press release from Medline about Gunter Kampf’s study "Efficacy of ethanol-based hand foams using clinically relevant amounts: a cross-over controlled study among healthy volunteers." This study has several germane limitations in its design that may cause confusion in interpreting the conclusions of the study.

Based on the information contained in the press release, this study appears to be flawed in several key areas. The author establishes an arbitrary rub-in time of 30 seconds to justify testing a small volume of product. He then selects a European method (EN1500) that samples only the fingertips of human subjects and differs greatly from product application and use per U.S. guidelines and FDA proposed efficacy criteria1. The U.S. Centers for Disease Control and Prevention (CDC) has identified hand hygiene products with 62% alcohol content as meeting the requirements for an effective hand sanitizer in healthcare settings. Also, the FDA has utilized expert panels and reviewed submitted data to verify that products containing 60-95% ethanol are effective when properly formulated. The European standard does not apply in the U.S.2 STERIS stands behind the clinical performance of Alcare Plus Antiseptic Handrub with Emollients, Alcare Foamed Antiseptic Handrub, and Soft ‘N Sure Foamed Antiseptic Handrub based on the results obtained by studies conducted within the FDA proposed testing methodology.

Furthermore, this study incorrectly implies that foamed alcohol sanitizers differ significantly from alcohol gel or liquid sanitizers for rub-in characteristics. The amount of gel, liquid or foam products will have very similar rub-in times based on a liquid volume amount. Both gel and foam sanitizers "break" (become more liquid) once friction is applied during application and inherently 2.5 grams of foam (approximately a golf ball size) and 2.4 mL of gel will rub-in within similar time frames.

The author does accurately state that "real life in a practical setting" must be considered. In doing so, one must recognize that there is greater variation and potential impact based on hand size (i.e. surface area), skin condition, and room humidity, than the dosage form of a sanitizer (foam vs. gel or liquid). To note, the finger tip method outlined by this study does not account for these variations in the way the FDA proposed methods address this issue. The STERIS foam sanitizers allow users to adjust the dispensed quantity to adapt for these variations. Interestingly, the study’s author fails to address the U.S. preference for foam sanitizers. STERIS recognizes that when healthcare workers have a product they like, they will use it. If the goal in hospitals is good hand hygiene practices and compliance that results in infection prevention, this is no small point.

Healthcare personnel typically rub in these products "on-the-go"; one of the major advantages for this product category is not being tied to a sink. The suggestion that 1.6 grams of just water will provide the same efficacy as the same quantity of 62% ethanol foam sanitizer is an incredulous statement in light of overwhelming evidence to the contrary. This statement implies that hand hygiene practices should go back to the sink. While STERIS fully supports the use of soap and water as a critical component of an effective hand hygiene program, the use of wash products take longer to wash, rinse and dry than is needed for foam alcohols products to rub in. This seems illogical if the author’s primary concern is time needed for hand hygiene events.

It is important that proper context and U.S. standards as defined by the FDA and CDC are applied when studies are presented that seem to make blanket statements about important infection prevention products being widely used in U.S. hospitals today.

Charlie Kilfoyle, Sr. Product Manager
Skin Care and Surface Disinfectants
STERIS Corporation

References

1. Food and Drug Administration. Topical antimicrobial drug products for over-the-counter human use; tentative final monograph for health care antiseptic drug products-proposed rule. Federal Register, Parts 333 and 369, Vol 59, No 116, June 17, 1994; pp. 31402-31452.

2.CEN (European Committee for Standarization) EN 1500. Chemical disinfectants and antiseptics-hygenic handrub: test method and requirements (phase 2, step 2. Brussels:CEN, 1997.

Trend Update
2010 Top Trends for the healthcare supply chain

The following trends are from the

  1. Emphasis on the importance of the supply chain for overall organizational success. Greater involvement of supply chain in broad accountability and participation in decision-making. Focus on the priority of supply chain for the organization.

  2. Specification of supply chain as an area where organizational cost savings can continue to be generated. Focus on supply utilization, total cost in use and overall excellence in supply chain management.

  3. Increased attention to the importance of supply chain in organizational collaboration. Achieved through operational excellence, credibility, accountability, trust and relationship building.

  4. Priority placed on the need for more, better and actionable data. Greater supply chain efficiency, cost savings and transparency all hinge on better data.

  5. More emphasis on the link between supply chain and clinical care and outcomes. Comparative effectiveness research, evidence of superiority, quality and patient centered health care are all important considerations for optimal supply chain management.

  6. Greater emphasis on development and incorporation of successful physician engagement strategies. Continued push to involve physicians in management of the materials environment and to bring their clinical expertise to the table.

  7. Increased attention to adoption of data standards for product and location identification. Patient safety, supply chain efficiency and cost savings are all linked to this effort.

  8. Assessment of value received from fees paid supply chain trading partners. Desire for value based rather than fee-based relationships.

  9. Push for models of collaboration with trading partners.

  10. Greater attention to strategy enhancing and “smart” products. Products that contribute to broader organizational goals such as sustainability or improvement of patient satisfaction and products that can provide additional data.

  11. Increased focus on global sourcing. Assessment of both opportunities and risks associated with global sourcing activities as well as the costs associated with seeking out and securing new suppliers.

  12. Assessment of the effect of health reform law on the supply chain. How will provisions to expand coverage, improve health care delivery system, and continued support for comparative effectiveness research affect the supply chain.

For further information contact:
Eugene S. Schneller, Ph.D., Co-Director, Health Sector Supply Chain Research Consortium,
Gene.schneller@asu.edu or Natalia Wilson, M.D., MPH, Co-Director, Health Sector Supply Chain Research Consortium, Natalia.wilson@asu.edu.
http://wpcarey.asu.edu/hsrc